Chang Yu Wang

Array ( [id] => 17720466 [patent_doc_number] => 20220213186 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-07 [patent_title] => COMPOSITION FOR PREVENTING OR TREATING BRAIN AND NERVOUS SYSTEM DISEASE [patent_app_type] => utility [patent_app_number] => 17/440733 [patent_app_country] => US [patent_app_date] => 2020-03-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13503 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17440733 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17643192 [patent_doc_number] => 20220170930 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-02 [patent_title] => METHOD FOR SCREENING COMPOUND FOR TREATING OR PREVENTING POLYQ-RELATED NEURODEGENERATIVE DISEASES [patent_app_type] => utility [patent_app_number] => 17/437968 [patent_app_country] => US [patent_app_date] => 2020-03-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18206 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17437968 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16569171 [patent_doc_number] => 20210008177 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-14 [patent_title] => Elapidae neurotoxin enhances opioid analgesic effect and inhibits opioid induced hyperalgesia and tolerance [patent_app_type] => utility [patent_app_number] => 16/812529 [patent_app_country] => US [patent_app_date] => 2020-03-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5042 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -3 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16812529 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16091087 [patent_doc_number] => 20200199530 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-25 [patent_title] => METHODS OF DIFFERENTIATING STEM CELL-DERIVED ECTODERMAL LINEAGE PRECURSORS [patent_app_type] => utility [patent_app_number] => 16/809792 [patent_app_country] => US [patent_app_date] => 2020-03-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 43862 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 69 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16809792 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17627557 [patent_doc_number] => 20220162572 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-26 [patent_title] => NUCLEIC ACID CONSTRUCT ENCODING Trk FRAGMENT AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/436256 [patent_app_country] => US [patent_app_date] => 2020-03-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7476 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17436256 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17505187 [patent_doc_number] => 20220098289 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-31 [patent_title] => THERAPEUTIC TARGET AND MONOCLONAL ANTIBODIES AGAINST IT FOR THE DIAGNOSIS AND TREATMENT OF ALZHEIMER'S DISEASE [patent_app_type] => utility [patent_app_number] => 17/428588 [patent_app_country] => US [patent_app_date] => 2020-02-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18095 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17428588 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16512959 [patent_doc_number] => 20200392217 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-17 [patent_title] => HUMAN-DERIVED ANTI-HUNTINGTIN (HTT) ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/784645 [patent_app_country] => US [patent_app_date] => 2020-02-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 54255 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16784645 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17143062 [patent_doc_number] => 20210311075 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-07 [patent_title] => METHODS FOR DETECTING DISORDERS RELATED TO CALCIUM DISCHARGE FROM INTRACELLULAR STORES [patent_app_type] => utility [patent_app_number] => 16/776396 [patent_app_country] => US [patent_app_date] => 2020-01-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15408 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -37 [patent_words_short_claim] => 164 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16776396 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16557231 [patent_doc_number] => 20210002379 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-07 [patent_title] => METHODS AND COMPOSITIONS FOR INCREASING N-ACETYLGLUCOSAMINIDASE ACTIVITY IN THE CNS [patent_app_type] => utility [patent_app_number] => 16/746847 [patent_app_country] => US [patent_app_date] => 2020-01-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32362 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16746847 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17776588 [patent_doc_number] => 20220242937 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-04 [patent_title] => HUMANIZED ANTI-A[BETA] MONOCLONAL ANTIBODY AND APPLICATION THEREOF [patent_app_type] => utility [patent_app_number] => 17/427589 [patent_app_country] => US [patent_app_date] => 2020-01-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14255 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17427589 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17776587 [patent_doc_number] => 20220242936 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-04 [patent_title] => HUMANIZED ANTI-A[BETA] MONOCLONAL ANTIBODY AND APPLICATION THEREOF [patent_app_type] => utility [patent_app_number] => 17/427584 [patent_app_country] => US [patent_app_date] => 2020-01-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14398 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17427584 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17548191 [patent_doc_number] => 20220119532 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-21 [patent_title] => USE OF INTEGRIN INHIBITORS FOR TREATMENT OR PREVENTION OF A NEUROLOGICAL IMMUNITY DISORDER AND/OR NERVOUS SYSTEM INJURY [patent_app_type] => utility [patent_app_number] => 17/422659 [patent_app_country] => US [patent_app_date] => 2020-01-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23945 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17422659 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15831909 [patent_doc_number] => 20200131236 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-04-30 [patent_title] => TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS [patent_app_type] => utility [patent_app_number] => 16/739561 [patent_app_country] => US [patent_app_date] => 2020-01-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16137 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16739561 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16206968 [patent_doc_number] => 20200239958 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-30 [patent_title] => METHODS OF PREDICTING THE DEVELOPMENT OF COMPLEMENT-MEDIATED DISEASE [patent_app_type] => utility [patent_app_number] => 16/734168 [patent_app_country] => US [patent_app_date] => 2020-01-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38102 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 79 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16734168 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16614944 [patent_doc_number] => 20210033597 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-04 [patent_title] => METHOD FOR IDENTIFYING EFFECTIVE TREATMENTS AGAINST NEURODEGENERATIVE DISORDERS [patent_app_type] => utility [patent_app_number] => 16/732109 [patent_app_country] => US [patent_app_date] => 2019-12-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10720 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16732109 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17426899 [patent_doc_number] => 20220054607 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-24 [patent_title] => GLIAL FIBRILLARY ACIDIC PROTEIN TARGETING IMMUNO- AND APTAMER-BASED-THERAPY FOR NEUROINJURY, NEURODEGENERATION, NEURO-DISEASE, AND NEURO-REPAIR [patent_app_type] => utility [patent_app_number] => 17/413835 [patent_app_country] => US [patent_app_date] => 2019-12-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15577 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17413835 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17823754 [patent_doc_number] => 11428698 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-08-30 [patent_title] => Neuronal viability factor and use thereof in Alzheimer's disease [patent_app_type] => utility [patent_app_number] => 16/711492 [patent_app_country] => US [patent_app_date] => 2019-12-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 10 [patent_no_of_words] => 8147 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 90 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16711492 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16421925 [patent_doc_number] => 20200347123 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-05 [patent_title] => METHODS FOR TREATING SPINAL CORD INJURY AND PAIN [patent_app_type] => utility [patent_app_number] => 16/710757 [patent_app_country] => US [patent_app_date] => 2019-12-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21857 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 138 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16710757 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18084377 [patent_doc_number] => 11534484 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-12-27 [patent_title] => Mimotopes of alpha-synuclein and vaccines thereof for the treatment of synucleinopathy [patent_app_type] => utility [patent_app_number] => 16/709999 [patent_app_country] => US [patent_app_date] => 2019-12-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 10 [patent_no_of_words] => 8176 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 62 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16709999 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17399607 [patent_doc_number] => 20220041697 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-10 [patent_title] => MONOCLONAL ANTIBODIES TARGETING C-TERMINAL REGION OF PHOSPHORYLATED TAU [patent_app_type] => utility [patent_app_number] => 17/312854 [patent_app_country] => US [patent_app_date] => 2019-12-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21352 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17312854 [rel_patent_id] =>[rel_patent_doc_number] =>)